The Tumor Suppressor Smad4/DPC4 Is Regulated by Phosphorylations that Integrate FGF, Wnt, and TGF-β Signaling  by Demagny, Hadrien et al.
ArticleThe Tumor Suppressor Smad4/DPC4 Is Regulated by
Phosphorylations that Integrate FGF, Wnt, and TGF-b
SignalingGraphical AbstractHighlightsThe tumor suppressor Smad4 is regulated by FGF/MAPK and
Wnt/GSK3 phosphorylations
Sequential phosphorylations control both Smad4 activity and
degradation by b-TrCP
In the presence of FGF,Wnt potentiates TGF-b at low physiolog-
ical concentrations
This mechanism controls germ layer and organizer specification
in XenopusDemagny et al., 2014, Cell Reports 9, 688–700
October 23, 2014 ª2014 The Authors
http://dx.doi.org/10.1016/j.celrep.2014.09.020Authors
Hadrien Demagny, Tatsuya Araki,




Demagny et al. show that Smad4 is phos-
phorylated after FGF primes three inhibi-
tory phosphorylations by GSK3. In the
presence of FGF and Wnt, signaling by
low concentrations of TGF-b is greatly
enhanced, helping explain the devas-
tating effects of loss of the tumor sup-
pressor Smad4.
Cell Reports
ArticleThe Tumor Suppressor Smad4/DPC4 Is Regulated
by Phosphorylations that Integrate FGF, Wnt,
and TGF-b Signaling
Hadrien Demagny,1 Tatsuya Araki,1 and Edward M. De Robertis1,*




This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY
Smad4 is a major tumor suppressor currently
thought to function constitutively in the transforming
growth factor b (TGF-b)-signaling pathway. Here,
we report that Smad4 activity is directly regulated
by the Wnt and fibroblast growth factor (FGF) path-
ways through GSK3 and mitogen-activated protein
kinase (MAPK) phosphorylation sites. FGF acti-
vates MAPK, which primes three sequential GSK3
phosphorylations that generate a Wnt-regulated
phosphodegron bound by the ubiquitin E3 ligase
b-TrCP. In the presence of FGF, Wnt potentiates
TGF-b signaling by preventing Smad4 GSK3 phos-
phorylations that inhibit a transcriptional activation
domain located in the linker region. When MAPK
is not activated, the Wnt and TGF-b signaling path-
ways remain insulated from each other. In Xenopus
embryos, these Smad4 phosphorylations regulate
germ-layer specification and Spemann organizer for-
mation. The results show that three major signaling
pathways critical in development and cancer are
integrated at the level of Smad4.
INTRODUCTION
Smad4, also known as deleted in pancreatic carcinoma 4
(DPC4), is amajor tumor suppressor gene that constrains cancer
growth. Pancreatic, colorectal, and prostate carcinomas prolif-
erate rapidly and progress toward metastases when Smad4
function is lost (Levy and Hill, 2006; Ding et al., 2011; Massague´,
2012). Transforming growth factor b (TGF-b) receptors signal by
phosphorylating carboxy-terminal serines of the transcription
factors Smad1/5/8 (for bone morphogenetic proteins [BMPs])
or Smad2/3 (for TGF-b/activin). These receptor-activated Smads
(R-Smads) then undergo a second set of phosphorylations in the
linker region via activation of tyrosine kinase receptors such as
those for fibroblast growth factor (FGF) and epidermal growth
factor (EGF) (Kretzschmar et al., 1997; Pera et al., 2003; Sapkota
et al., 2007; Fuentealba et al., 2007; Millet et al., 2009) or through
nuclear CDK8 and CDK9 (Alarco´n et al., 2009; Gao et al., 2009;688 Cell Reports 9, 688–700, October 23, 2014 ª2014 The AuthorsArago´n et al., 2011). These prime phosphorylations by glycogen
synthase kinase-3 (GSK3) that target R-Smads for proteasomal
degradation (Fuentealba et al., 2007; Sapkota et al., 2007). The
transcription factor Smad4 functions as a co-Smad that binds
to R-Smads and has been considered a constitutively active
component of the pathway (Massague´, 2012).
The Wnt pathway is activated in the early stages of many
tumors, and its transcriptional effects are mediated by the sta-
bilization of b-catenin (Clevers and Nusse, 2012). Canonical
Wnt signaling causes the sequestration of cytosolic GSK3,
axin, and Dishevelled in multivesicular bodies (Taelman et al.,
2010; Vinyoles et al., 2014). In addition to b-catenin, other pro-
teins may be regulated by Wnt signaling through the decrease in
GSK3 phosphorylations that are normally recognized as phos-
phodegrons to be polyubiquitinated and degraded in the pro-
teasome (Kim et al., 2009; Taelman et al., 2010; Vinyoles
et al., 2014; Acebron et al., 2014). GSK3 is a kinase that prefers
prephosphorylated substrates, introducing phosphorylations
on Ser or Thr residues located four amino acids upstream
(S/TxxxS/T[PO3]; Cohen and Frame, 2001). During a bio-
informatic screen of the human proteome, we noticed that
Smad4 contains three putative GSK3 phosphorylation sites
primed by a mitogen-activated protein kinase (MAPK) site
(PxTP; Taelman et al., 2010).
Here, we report that Smad4 activity depends on tyrosine
kinase/MAPK- and Wnt/GSK3-regulated phosphorylations,
revealing a node of signaling integration between these two
main oncogenic pathways and the TGF-b tumor suppressor
signal. We show that, when cells received an FGF signal, phos-
phorylation of the MAPK site promoted Smad4 peak transcrip-
tional activity before priming inhibitory GSK3 phosphorylations.
Smad4 phosphorylation by GSK3 created a phosphodegron
that led to its subsequent polyubiquitination and degradation
by the E3-ligase b-TrCP. In the presence of Wnt, Smad4 GSK3
phosphorylations were inhibited and the TGF-b signal was pro-
longed, particularly at low levels of TGF-b ligands. Replacing
Smad4 with a GSK3-resistant mutant showed that the crosstalk
between TGF-b and Wnt is mediated by Smad4. This molecular
mechanism, in which Wnt and MAPK activation enhance anti-
proliferative TGF-b signals, may help understand the role of
Smad4 as a barrier to tumor progression. In the context of the
Xenopus embryo, we found that replacing endogenous Smad4
with a GSK3 phosphorylation-resistant mutant converted the
Figure 1. The Smad4 Linker Region Is
Phosphorylated by GSK3
(A) Smad4 contains MAPK (blue) and GSK3 (red)
phosphorylation sites in its linker region.
(B) Endogenous FGF-induced pSmad4GSK3
phosphorylation requires Erk activity in serum-
depleted NIH 3T3 cells stimulated with FGF2 for
1 hr.
(C) Endogenous pSmad4GSK3 antigen is induced
by a 1 hr FGF2 treatment, inhibited by pre-
incubation withWnt3a for 5 hr, and blocked by the
GSK3 inhibitor BIO.
(D–F) Mn2+-Phos-tag analysis of endogenous
Smad4 in NIH 3T3 cells cultured in the absence of
serum.
(G) Diagrams of Smad4 constructs encoding
Smad4 wild-type (Smad4-WT) or phosphoryla-
tion-resistant mutants (Thr to Val) for MAPK
(Smad4-MM) and GSK3 (Smad4-GM) sites.
(H) GSK3 phosphorylations require an intact
MAPK site in transfected 3T3 cells.
See also Figure S1.entire ectoderm into mesoderm and expanded Spemann orga-
nizer formation, indicating that the growth-factor-regulated
Smad4 phosphorylations play an important role in animal
development.
RESULTS
Wnt and FGF Regulate Phosphorylation of Smad4 Linker
Region
The putative regulatory sites consisted of four threonines located
in the linker (middle) region of Smad4 (Figure 1A). To determine
whether Smad4 was phosphorylated by GSK3, we generated
an antibody raised against phospho-threonines 273 and 269
(pSmad4GSK3 Ab). Because the priming site was a canonical
MAPK/Erk site (PxTP), we treated 3T3 fibroblasts with FGF2
and found that a single band of endogenous pSmad4GSK3 anti-
gen was increased (Figure 1B, lanes 1 and 2). The pSmad4GSK3
signal was blocked by treatment with the MEK-specific inhibitor
U0126, demonstrating a requirement for Erk/MAPK downstream
of FGF stimulation (Figure 1B, lane 3). FGF-induced pSmad4GSK3
phosphorylation was inhibited by preincubation with Wnt3a pro-
tein (Figure 1C, lanes 2 and 3) and blocked by the GSK3 inhibitor
BIO (Figure 1C, lane 4). The specificity of the antibody was
confirmed by Smad4 small interfering RNA (siRNA) depletion
and phosphatase treatment (Figure S1).
To determine the number of sites that were phosphorylated,
we separated proteins from untransfected 3T3 cells in polyacryl-Cell Reports 9, 688–700,amide SDS gels containing the phos-
phate-binding compound Mn2+-Phos-
tag (Kinoshita et al., 2006). In the
absence of serum, a single band was
detected by a Smad4 monoclonal anti-
body, whereas upon addition of FGF,
four additional bands were displayed
(Figure 1D, lanes 1 and 2). The three
slower migrating bands were also posi-tive for pSmad4GSK3 antibody (Figure 1E). GSK3 inhibition by
LiCl resulted in the accumulation of the monophosphorylated
form, whereas treatment with U0126 eliminated all Smad4 phos-
phorylations (Figure 1F, lanes 3 and 4). Studies with transfected
phosphorylation-resistant MAPK or GSK3 mutants (designated
as Smad4-MM and Smad4-GM, respectively, Figure 1G)
showed that the priming site (threonine 277) was required for
GSK3 phosphorylations (Figure 1H). Taken together, these re-
sults demonstrate that Smad4 is regulated by sequential phos-
phorylations as proposed in Figure 1A.
Wnt/GSK3 Regulates the Polyubiquitination and
Degradation of Smad4
Polyubiquitination of R-Smads is controlled by linker phosphor-
ylations (Sapkota et al., 2007; Fuentealba et al., 2007; Gao et al.,
2009), prompting us to investigate the effects of GSK3 phos-
phorylations on Smad4 stability. HaCaT keratinocytes (which
respond well to TGF-b and siRNA transfection, but not to
FGF) were treated with a 20 min pulse of EGF and found
that pSmad4GSK3 was degraded over a period of 4 hr (Fig-
ure 2A). Proteasomal inhibition by MG-132 greatly stabilized
the phosphorylated form of Smad4 (Figure 2A), indicating that
pSmad4GSK3 was preferentially degraded by the proteasome.
Immunoprecipitation studies showed that endogenous Smad4
polyubiquitination was increased by FGF treatment and required
GSK3 activity (Figures 2B and S2C), as well as intact phosphor-
ylation sites for GSK3 and MAPK (Figure 2C).October 23, 2014 ª2014 The Authors 689
Figure 2. Wnt-Regulated GSK3 Phosphorylations Control Smad4 Polyubiquitination and Degradation
(A) Time course of pSmad4GSK3 phosphorylation primed by a 20 min pulse of EGF in HaCaT cells, showing that the proteasome inhibitor MG-132 preferentially
prolongs the half-life of pSmad4GSK3.
(B) Endogenous Smad4 polyubiquitination is increased by FGF and requires GSK3 activity (in the presence of the proteasome inhibitor MG132). Before
immunoprecipitation with monoclonal Smad4 antibody, 0.2% SDS was added, samples heated at 95C for 10 min to break protein-protein interactions, and
diluted 10-fold with RIPA buffer to ensure that the polyubiquitinated bands detected were not ubiquitinated Smad4-interacting proteins (Zhu et al., 1999). For 5%
input loading, see Figure S2A. Ip, immunoprecipitation; wb, western blotting.
(C) Smad4 polyubiquitination requires intact MAPK and GSK3 sites; Flag-Smad4 or its phosphorylation-resistant mutants were cotransfected with HA-ubiquitin
into FGF-treated HEK293 cells and immunoprecipitated (Zhu et al., 1999) with anti-Flag antibodies. For 5% input loading, see Figure S2B.
(D) Wnt3a or LiCl treatment extended the half-life of endogenous Smad4 exclusively in FGF-treated 3T3 cells. Note that, in the absence of FGF, Smad4 has a
longer half-life. Similar results were obtained in two independent experiments.
(D’) Quantification of western results shown in (D).
(E) Smad4 protein is stabilized by microinjection of xWnt8 mRNA in Xenopus-dissociated animal cap cells. In dissociated cells, dpErk is activated, causing
increased pSmad4GSK3 and Flag-Smad4 degradation (lane 6). Both GSK3 phosphorylation and Flag-Smad4 degradation were blocked by coinjection of Wnt8
mRNA (lane 7). Smad4 degradation in microinjected embryos required intact GSK3 phosphorylation sites and was blocked by the Erk pathway inhibitor U0126
(40 mM). Cells were harvested at stage 10.5, early gastrula.
See also Figure S2.Because GSK3 is a Wnt-regulated kinase, we asked whether
the Wnt growth factor could regulate Smad4 stability. In cyclo-
heximide time course experiments, endogenous Smad4 was
stabilized by addition of Wnt3a or of the GSK3 inhibitor LiCl
but only in FGF-treated 3T3 cells (Figures 2D and 2D’). Xenopus
animal caps explants microinjected with Flag-tagged Smad4690 Cell Reports 9, 688–700, October 23, 2014 ª2014 The AuthorsmRNAs were also used to study the degradation of Smad4;
because mRNAs were injected, any differences in protein levels
should be posttranscriptional. In Xenopus ectodermal explants,
a potent and sustained activation of the MAPK/Erk pathway is
achieved by cell dissociation (Kuroda et al., 2005). We found
that, in dissociated animal cap cells, diphospho Erk was
Figure 3. The Wnt-Regulated Smad4 GSK3 Phosphodegron Is Bound by the Ubiquitin E3-Ligase b-TrCP and Targeted for Degradation
(A) Endogenous binding between Smad4 and b-TrCP is increased by FGF and blocked by Wnt3a treatment. Immunoprecipitation of endogenous Smad4 from
untransfected 3T3 cells using a Smad4 monoclonal antibody bound to protein A/G agarose beads; 5% loading of initial lysate is shown in Figure S3B.
(B) FGF-induced binding between Smad4 and b-TrCP requires intact GSK3 phosphorylation sites in transfected 293 cells. Flag-tagged Smad4-WT bound HA-
tagged b-TrCP in the presence of FGF, but phosphorylation-resistant Smad4-GM was unable to coprecipitate with b-TrCP; 5% loading is shown in Figure S3C.
(C) Smad4 polyubiquitination induced by the oncogenic RasG12V protein is mediated by b-TrCP; 5% loading is shown in Figure S3D.
(D) b-TrCP depletion with siRNA prolongs the half-life of pSmad4GSK3 induced by a 20 min pulse of EGF in HaCaT cells.
(E) Transfection of DN-b-TrCP significantly increased TGF-b signaling in Smad4/ MB-468 cells transfected with hSmad4-WT. DN-b-TrCP had no significant
effect in Smad4-GM-expressing MB-468 cells. Note that b-TrCP limits TGF-b signaling and that this requires the Smad4 GSK3 phosphorylation sites.
(F) Diagram of the proposed Smad4 phosphodegron recognition by b-TrCP.
See also Figure S3.activated, the Smad4 GSK3 sites were strongly phosphorylated,
and, importantly, Flag-Smad4 was degraded (Figure 2E, lane 6).
The phosphorylation by GSK3 and the degradation of Smad4
were dependent on MAPK/Erk activity as they were blocked by
U0126 treatment (Figure 2E, lane 10). Coinjection of Wnt8
mRNA inhibited Smad4 phosphorylation by GSK3 and pre-
vented Flag-Smad4-wild-type (WT) degradation (Figure 2E,
compare lanes 6 and 7). Importantly, the GSK3 phosphoryla-
tion-resistant Smad4 mutant (Flag-Smad4-GM) was insensitive
to stabilization by Wnt8 (Figures 2E, S2D, and S2D’).
Taken together, these experiments show that linker phosphor-
ylations regulated by FGF/MAPK and Wnt/GSK3 control Smad4
polyubiquitination and degradation.
Wnt/GSK3 Regulates a Smad4 b-TrCP Phosphodegron
We next analyzed the molecular mechanism by which Smad4
phosphorylations regulated its polyubiquitination. Smad4 prote-Colysis is mediated by interaction with the F-box E3 ubiquitin
ligase b-TrCP but was not previously known to be regulated by
growth factor signaling (Wan et al., 2004, 2005; Yang et al.,
2006). Because b-TrCP recognizes phosphodegrons (Fuchs
et al., 2004), we investigated whether its binding to Smad4
was regulated rather than constitutive. Immunoprecipitation
studies with endogenous proteins showed that b-TrCP bound
preferentially to Smad4 in the presence of FGF and that Wnt3a
treatment prevented this interaction in untransfected 3T3 cells
(Figure 3A, lanes 3 and 4). We also found that intact GSK3 phos-
phorylation sites in Smad4 were essential for the FGF-induced
binding of b-TrCP to Smad4 (Figure 3B, lanes 3 and 5). Finally,
a dominant-negative form of b-TrCP (DN-b-TrCP lacking the
F-box domain; Orian et al., 2000) inhibited the polyubiquitination
of Smad4 induced by RasG12V (Figure 3C).
To test whether b-TrCP was the E3 ligase responsible for
pSmad4GSK3 degradation, we depleted HaCaT cells of b-TrCPell Reports 9, 688–700, October 23, 2014 ª2014 The Authors 691
with an siRNA that targets both b-TrCP1 and b-TrCP2 (Guarda-
vaccaro et al., 2003). GSK3 phosphorylation of Smad4
was primed by a 20 min pulse of EGF, and we found that
b-TrCP depletion strongly stabilized the pSmad4GSK3 form (Fig-
ure 3D). Finally, in a functional reporter gene assay, DN-b-TrCP
increased responsiveness to TGF-b, and this effect required
intact Smad4 GSK3 sites (Figure 3E).
Taken together, these experiments indicate that MAPK and
GSK3 trigger the formation of a phosphodegron bound by the
E3 ligase b-TrCP, causing the polyubiquitination of Smad4 as
indicated in the model in Figure 3F.
Wnt and TGF-b Signaling Crosstalk via Smad4
A central question is whether the TGF-b, FGF, and Wnt
signaling pathways are insulated from each other or integrated
via the Smad4 phosphorylation sites. To address this, human
embryonic kidney 293 (HEK293) cells were transfected with
the TGF-b-specific reporter CAGA12-luciferase (Dennler et al.,
1998) and treated with or without Wnt3a. TGF-b signaling was
unaffected by Wnt3a (Figure 4A, bars 2 and 4), as expected if
the two pathways were distinct and insulated from each other.
However, addition of FGF2 reduced TGF-b signaling by two
thirds (Figure 4A, bar 6), presumably by priming inhibitory
GSK3 phosphorylations. Importantly, in the presence of FGF2,
Wnt3a was able to stimulate TGF-b signaling, reaching signaling
levels higher than those of TGF-b alone (Figure 4A, see brackets).
Wnt also potentiated expression levels of the endogenous
TGF-b target genes PAI-1 and Smad7 in HepG2 cells (Figures
4B, S4A, and S4B), and the stimulation of TGF-b signaling by
Wnt was mimicked by the GSK3 inhibitor LiCl (Figures S4C
and S4D). A DN-Tcf3 construct (Molenaar et al., 1996) did not
affect the crosstalk between TGF-b, FGF, and Wnt3a, indicating
that this mechanism is independent of Tcf3/b-catenin-mediated
transcription (Figure S4E). We note that the stimulation of TGF-b
signaling byWnt was not observed in confluent cell cultures (Fig-
ure S4F), as is the case with other TGF-b effects (Varelas et al.,
2010).
In addition, a BMP reporter gene (BRE-Luc; Korchynskyi and
ten Dijke, 2002) was also regulated by Wnt in the presence of
FGF (Figures S4G and S4H), indicating that the Smad4 regulato-
ry mechanism described here applies to both the TGF-b and
BMP branches of the pathway. These experiments showed
that Wnt enhances TGF-b signaling but only when MAPK/Erk is
activated by FGF.
We then investigated the extent to which the observed cross-
talk between TGF-b and Wnt signaling was mediated by the
linker GSK3 phosphorylations in Smad4. The receptor-regulated
Smad2/3 contains linker SP sites as well as an unprimed GSK3
site in the DNA-binding domain of Smad3 (Guo et al., 2008; Millet
et al., 2009, Abushahba et al., 2012). To assess specifically the
role of Smad4, we used mammary carcinoma MDA MB-468
cells, which lack endogenous Smad4 and TGF-b responsiveness
(de Caestecker et al., 2000). Transfection of Smad4-WT restored
TGF-b signaling, which was potentiated by Wnt in the presence
of EGF (Figure 4C, bars 5 and 6). However, when cells were
transfected with the GSK3 phosphorylation-resistant Smad4-
GM, TGF-b caused a strong signal but lost all regulation by
Wnt3a (Figure 4C, bars 8 and 9). Because replacing Smad4 by692 Cell Reports 9, 688–700, October 23, 2014 ª2014 The Authorsa GSK3-insensitive mutant eliminated Wnt potentiation, we
conclude that the observed crosstalk between TGF-b and
Wnt is mediated through the GSK3 phosphorylation sites of
Smad4 and not by other components of the signal transduction
pathway.
The potent stimulatory effect of Wnt on TGF-b signaling was
concentration dependent and best revealed in 293 cultured cells
treated with FGF and variable amounts of TGF-b (Figure 4D).
When the same data were displayed as shown in Figure 4E, it
was observed that, in the absence of Wnt3a (and presence of
FGF), 100 ng/ml TGF-b was required for a 240-fold induction
of CAGA12-Luc, whereas in the presence of Wnt3a, only 1 ng/
ml TGF-b was sufficient to reach a similar transcriptional
activation.
We also examined how Wnt affected the time course of
the TGF-b transcriptional response (Figure 4F). HaCaT cells
were treated with a 15 min pulse of 1 ng/ml TGF-b, which was
terminated by adding 2 mM of the type I TGF-b receptor inhibitor
SB-431542 (Halder et al., 2005). Analyses of transcripts for
the TGF-b target gene PAI-1 showed that Wnt significantly pro-
longed the TGF-b transcriptional response (Figure 4F).
From these functional experiments, we conclude that,
although TGF-b and Wnt signaling are insulated in the absence
of FGF, activation of the MAPK pathway causes a robust cross-
talk in which canonical Wnt enhances and prolongs signaling
by low, presumably the most physiologically relevant, levels of
TGF-b ligands.
The Smad4 Linker Contains a Growth-Factor-Regulated
Transcriptional Activation Domain
A short region of the linker has been identified as a Smad4 acti-
vation domain (SAD) (de Caestecker et al., 2000). This 48-amino-
acid sequence binds the transcriptional coactivator p300/CBP
and contains the MAPK site, but not the GSK3 sites. We asked
if a construct containing the entire linker domain (169 amino
acids) could be regulated by FGF and Wnt. The Smad4 linker
region was fused to the yeast Gal4 DNA-binding domain
(Gal4DBD) (Figure 5A) and used in transcriptional assays with
an upstream activating sequence (UAS)-Gal4-luciferase reporter
gene (de Caestecker et al., 2000). The linker region of Smad4
was both required and sufficient to drive transcriptional activity
in a TGF-b-independent way (Figures S5A and S5B). Interest-
ingly, the activity of the transcription activation domain con-
tained in the linker region was repressed by FGF and significantly
increased by Wnt3a (Figure 5B, bars 2–4). When the GSK3 sites
were mutated (Gal4DBD-S4linker-GM), Wnt lacked any signifi-
cant effect (Figure 5B, bars 6 and 7). Surprisingly, FGF stimulated
the transcriptional activity of the S4linker-GM construct instead
of inhibiting it (Figures 5B, bars 5 and 6), indicating that MAPK
phosphorylation has a positive effect on the Smad4 transcription
factor (in the absence of GSK3 phosphorylations). In agreement
with this, mutation of theMAPK-priming site (Gal4DBD-S4linker-
MM) had very low levels of transcriptional activity (Figure 5B,
bars 8–10).
An important feature of the Gal4DBD-S4linker constructs is
that their stability was not affected by FGF or Wnt treatment
(Figure 5C). In RasG12V-transfected cells, Gal4DBD-S4linker-
WT was heavily phosphorylated by GSK3, but not degraded
Figure 4. Wnt and TGF-b Signaling Crosstalk via Smad4 GSK3 Phosphorylations
(A) TGF-b CAGA12-Luc reporter gene assays in 293 cells showing that Wnt potentiated TGF-b signaling but only in the presence of FGF (brackets).
(B) The endogenous TGF-b target gene PAI-1 was similarly regulated 3 hr after addition of TGF-b and FGF (HepG2 cells).
(C) TGF-b signaling was restored in MDA-MB-468 (Smad4/) cells by Smad4-WT. Note that Wnt3a regulation was lost when Smad4-WT was replaced by the
GSK3 phosphorylation-resistant mutant Smad4-GM.
(D) TGF-b concentration dependence of CAGA12-Luc expression in FGF2-treated 293 cells.
(E) Same data as in (D) displayed as curves, showing that Wnt3a is a very potent activator at low concentrations of TGF-b ligand.
(F) Time course analysis of the TGF-b transcriptional response after terminating 15 min of a pulse of a low amount of TGF-b with SB-431542. The induction of
PAI-1 transcripts was prolonged by Wnt3a treatment (in EGF-treated HaCaT cells).
See also Figure S4.(Figure 5D). In the same cells, endogenous Smad4 was destabi-
lized by the sustained Ras activation, and its steady-state levels
were restored by a dominant-negative form of GSK3 (Figure 5D,
lanes 3 and 4). Because the stability of the Gal4-DBD constructCwas unchanged by phosphorylation of the linker sites, the induc-
tion of the UAS-luciferase reporter allowed the measurement of
transcriptional responses independently of changes in protein
stability.ell Reports 9, 688–700, October 23, 2014 ª2014 The Authors 693
Figure 5. The Smad4 Linker Domain Con-
tains a Growth-Factor-Regulated Tran-
scriptional Activation Domain
(A) Diagram of the yeast Gal4 DNA-binding
domain (Gal4DBD) fused to Smad4 linker region
and of the phosphorylation-resistant mutants
used to test transcriptional activation.
(B) UAS-Gal4-luciferase reporter gene assays in
293 cells showing that the linker transcriptional
activation domain was regulated by FGF andWnt.
(C) Western blot showing that Gal4DBD-S4linker
protein levels remained unchanged by FGF and
Wnt treatment despite the differences observed in
transcriptional activity.
(D) Gal4DBD-S4linker was heavily phosphory-
lated by GSK3 when cotransfected with activated
RasG12V, but its stability is not affected. In
contrast, endogenous Smad4was destabilized by
the sustainedMAPK activation driven by Ras, and
this required GSK3 activity.
(E) Model of Smad4 transcriptional activity regu-
lation by FGF and Wnt via the linker phosphory-
lation sites and binding of an as-yet-unknown
coactivator.
See also Figure S5.These results indicate that MAPK and GSK3 phosphorylations
regulate the activity of a transcriptional activation domain
located in the Smad4 linker region (Figure 5E). The phosphoryla-
tion of Smad4 linker region byMAPK andGSK3 initially regulates
its transcriptional activation domain and then facilitates its
degradation via the E3-ligase b-TrCP.
Phosphorylation by MAPK/Erk Promotes Smad4 Peak
Activity
To further investigate the function of the MAPK phosphorylation
site, we constructed a series of Smad4 mutants mimicking
different combinations of signaling events (Figure 6A). The
MAPK/Erk site (PxTP) located at position 277 was known to be
important for Smad4 nuclear translocation in response to TGF-
b treatment (Roelen et al., 2003). Using EGF-stimulated MDA
MB-468 Smad4/ cells, we found that a MAPK phosphoryla-
tion-resistant mutant (Smad4-MM) had lower levels of TGF-b694 Cell Reports 9, 688–700, October 23, 2014 ª2014 The Authorssignaling (Figure 6B, compare bars 4–6).
Smad4GM-MM, which differs by a single
amino acid (T277V) from Smad4-GM,
also had reduced activity (Figure 6B,
bars 8 and 10). These experiments indi-
cated that Thr 277 phosphorylation is
required for Smad4 peak activity.
In the absence of priming by EGF stim-
ulation, the crosstalk between TGF-b and
Wnt3a was not observed in Smad4WT
transfected MB-468 cells (Figure 6C,
compare bars 5 and 6). However, when
a phospho-mimetic amino acid was
introduced (T277D) at the MAPK site
(MAPK phospho-activated, Smad4-MA),
the enhancement of TGF-b signaling byWnt was restored (Figure 6C, compare bars 8 and 9). Wnt was
without effect when the GSK3 sites were also mutated
(Smad4GM-MA construct; Figure 6C, bars 11 and 12).
A similar requirement for the Smad4 MAPK site was found in
theXenopus embryo using an assay inwhich a low dose of b-cat-
enin mRNA (20 pg) was injected into a ventral blastomere to
induce partial secondary axes (Figure 6D). These axes were
blocked by coinjection of Smad4 antisense morpholinos (MOs)
(Dupont et al., 2009) but restored by hSmad4-WTmRNA (Figures
6E and 6F). Smad4-GM induced complete secondary axes with
heads, and this required a functional or phospho-mimetic 277
site (Figures 6G–6J and S6).
From these experiments, and others shown in this study, we
conclude that Smad4 phosphorylation at Thr 277 has a dual
function. First, it allows Smad4 to reach peak transcriptional ac-
tivity. Second, it primes Smad4 for GSK3 phosphorylations that
cause transcriptional inhibition and generate a phosphodegron
Figure 6. Phosphorylation of Threonine 277 Is Required for Smad4 Peak Activity
(A) Schematic diagrams of Smad4 phospho-resistant and phospho-mimetic mutants.
(B) Phosphorylation of theMAPK site (Thr 277) was required for Smad4maximal activity in the presence of EGF in Smad4/ cells. Brackets indicate that Smad4-
MM had decreased activity in the TGF-b pathway. The TGF-b receptor inhibitor SB-431542 (2 mM) was added in the indicated lanes to block autocrine TGF-b
derived from MDA-MB-468 cells; for results in the absence of SB-431542, see Figure S6B.
(C) In the absence of an EGF signal, mutation of the MAPK-priming site into a phospho-mimetic residue (T277D, Smad4-MA) restored the crosstalk betweenWnt
and TGF-b in transfected Smad4/ cells. Note also that Wnt potentiation of TGF-b signaling required functional Smad4 GSK3 sites.
(D) Twenty picograms of b-catenin mRNA injected ventrally at the four-cell stage is sufficient to induce a partial duplicated axis lacking head structures.
(E) Formation of b-catenin secondary axes required Smad4.
(F) Partial axes were rescued by 125 pg of hSmad4-WT mRNA coinjected together with b-catenin mRNA and Smad4 MOs.
(G) The same amount of mRNA encoding hSmad4-GM induced complete axis with eyes and cement gland (see arrow).
(H) In this assay, 125 pg of hSmad4GM-MM mRNA in which the MAPK site was mutated (T277V) was completely inactive. Note that this construct differs from
Smad4-GM by a single amino acid. This suggests that Smad4 activity requires an intact MAPK phosphorylation site in Xenopus embryos.
(I) hSmad4GM-MA in which the MAPK site was mutated into a phospho-mimetic aspartic acid induced the strongest complete axes, indicating a positive role for
the PxTP site.
(J) Quantification of the embryos microinjection results using the dorso-anterior index (DAI) (Kao et al., 1986) to measure the completeness of secondary axes;
similar results were obtained in three independent experiments.
See also Figure S6.that serves as a docking site for the ubiquitin E3 ligase b-TrCP.
Thus, both the activity and the stability of Smad4 are regulated
by FGF/EGF and Wnt.
Smad4 Regulation by GSK3 Determines Germ-Layer
Specification
The earlyXenopus embryo provides an excellent system to study
cell signaling. Using embryos depleted of endogenous Smad4
with MOs, we found that hSmad4-WT mRNA rescued expres-
sion of xBrachyury (a Nodal/TGF-bmesodermal target), whereas
the same amount of GSK3-resistant Smad4-GM showed a greatCincrease in signaling (Figures 7A–7D). The replacement of
endogenous Smad4 by Smad4-GM mRNA caused the entire
embryonic ectoderm to become mesoderm (Figure 7D). This
indicated that inhibition of Smad4 by GSK3 plays a crucial role
in allowing ectodermal differentiation in vivo.
Smad4-GM also caused a strong increase in Spemann orga-
nizer tissue marked by chordin mRNA in embryos depleted of
endogenous Smad4 (Figures 7E–7H). This suggested that
GSK3 activity may normally limit the size of the organizer through
Smad4. In Xenopus, Spemann organizer formation requires the
combined action of the maternal Wnt/b-catenin pathway andell Reports 9, 688–700, October 23, 2014 ª2014 The Authors 695
Figure 7. Smad4 Regulation by GSK3/Wnt
Is Involved in Germ-Layer Specification
and Organizer Formation in Xenopus
(A–D) Endogenous Smad4 replacement by
Smad4-GM, showing that GSK3 phosphorylation
was required for ectodermal specification in
Xenopus. The mesodermal marker xBrachyury
was greatly expanded when Smad4 GSK3 phos-
phorylations were prevented.
(E–H) The Spemann organizer gene chordin is
expanded by Smad4-GM injection.
(I) Diagram showing how maternal Wnt and zy-
gotic Nodal/TGF-b signals converge in early
Xenopus embryo patterning. GSK3 is proposed to
inhibit Nodal/Smad4 activity.
(J) In dissociated Xenopus animal cap cells,
xWnt8 mRNA potentiates signaling by 5 ng/ml
activin through the Smad4 GSK3 phosphorylation
sites. This experiment used a novel Smad4-lucif-
erase reporter designed for Xenopus assays and
shows that Wnt modifies the competence of cells
to activin induction through Smad4. Cells were
harvested when sibling embryos reached early
gastrula (stage 10.5).
(K) Three signaling pathways—Wnt, FGF, and
Nodal—converge on the dorsal side of the Xen-
opus embryo (stippled line) during Spemann
organizer formation.
See also Figure S7.of an early zygotic Nodal signal (Labbe´ et al., 2000; Reid et al.,
2012) as indicated in Figure 7I.
To test whether Wnt can directly regulate Smad4 through its
GSK3 sites in the embryo, we developed a sensitive synthetic
Smad4-luciferase reporter derived from the mouse chordin pro-
moter, described in Figure S7. Smad4-depleted embryos were
coinjected with the reporter and Smad4-WT or Smad4-GM, an-
imal cap cells dissociated, and treated with activin protein (Fig-
ure 7J). MicroinjectedWnt8mRNA potentiated activin signaling,
and this Wnt8 effect had a complete requirement for the GSK3
sites in Smad4 (Figure 7J, brackets). Because the Smad4 re-
porter gene does not respond to Wnt or Siamois (Figure S7E),
this result shows that the enhanced sensitivity to activin caused
by Wnt is mediated, at least in part, through the GSK3 phos-
phorylation sites in Smad4. In the Xenopus early blastula,696 Cell Reports 9, 688–700, October 23, 2014 ª2014 The Authorsthree signaling pathways—Wnt/b-cate-
nin, Nodal/pSmad2, and FGF/MAPK—
have been shown to be activated in the
dorsal region (Schohl and Fagotto,
2002). The convergence of these three
signals by the molecular mechanism
identified here helps explain the peak
Smad4 activity required for Spemann
organizer induction (Figure 7K).
DISCUSSION
The experiments reported here show
that Smad4, long thought to act as a
constitutively active component of theTGF-b andBMPpathways, is strongly regulated by growth factor
signaling through phosphorylation sites in its linker region. We
found that Smad4 is phosphorylated by GSK3 in response to
FGF. GSK3 phosphorylations have a double effect on Smad4.
First, they inhibit a transcription activation domain located in
the linker domain. Second, they generate a Wnt-regulated phos-
phodegron recognized by the E3 ligase b-TrCP. The molecular
mechanism discovered here provides a means of integrating
distinct pathways, which would otherwise remain insulated, al-
lowing cells to sense FGF and Wnt inputs and adapt TGF-b
outcome to their context.
Smad4 Activity Is Regulated by Growth Factors
Although the TGF-b pathway has been extensively studied for
more than two decades, many efforts have focused on R-Smads
regulation and less is known about Smad4. In this study, we
show that four phosphorylation sites located in the linker region
of Smad4 control its activity and stability in response to growth
factor stimulation. GSK3 phosphorylation is triggered by FGF
or EGF through activation of the Erk pathway. Phosphorylation
by growth factors via MAPK at Thr 277 allows Smad4 to reach
its peak of activity while priming it for subsequent inhibitory
GSK3 phosphorylations. The switch operated by GSK3 phos-
phorylation provides a way of controlling the duration of the
Smad4 signal by ensuring that degradation and turnover follow
transcriptional activation. Some of our experiments involved
phospho-resistant or phospho-mimetic mutations in Smad4,
which will cause exaggeration of the physiological effects (e.g.,
Smad4-GM mimics Smad4 receiving a maximal amount of
Wnt); however, all effects reported were also observed by
growth factor treatment of untransfected cells. Our observations
reconcile previous results in the literature that appeared to be
contradictory: it had been proposed that phosphorylation of
Thr 277 was required for Smad4 nuclear localization (Roelen
et al., 2003) and also for its degradation (Saha et al., 2001). How-
ever, regulation by FGF had not been addressed in these studies.
In recent work, Smad4 had been found to enter the nucleus in
transient pulses of about 30 min during TGF-b/BMP signaling
(Warmflash et al., 2012; Sorre et al., 2014). It will be very inter-
esting to investigate whether these bursts of nuclear localization
are controlled by the Smad4 growth-factor-regulated phosphor-
ylations described here.
Our finding that Wnt signals through Smad4 GSK3 sites and
can prolong the duration of a TGF-b pulse supports the view
that Smad4 phosphorylations are active regulators of TGF-b
signaling. The stimulatory effects of Wnt on TGF-b signaling
were entirely lost when Smad4-WT was replaced by the GSK3
phosphorylation-resistant Smad4-GM, both in human cultured
cells and in Xenopus embryos. This indicates that the crosstalk
between Wnt and TGF-b described here is mainly mediated by
Smad4 GSK3 sites and not by other components of the TGF-
b-signaling pathway. Perhaps the co-Smad Smad4 evolved a
specialized role in the integration of multiple signaling pathways.
Wnt and FGF/EGF growth factors had striking effects on
Smad4 transcriptional activity, particularly at low TGF-b concen-
trations (Figure 4). They also had an effect on Smad4 stability by
triggering the polyubiquitination and proteasomal degradation of
the fraction of Smad4 phosphorylated by MAPK and GSK3 (Fig-
ures 2 and 3). A short Smad4 activation domain (SAD) that con-
tains the MAPK site (but not the GSK3 sites) had been described
(deCaestecker et al., 2000).We now found that the linker domain
of Smad4 acts as a Wnt-stimulated activation domain indepen-
dently of protein degradation (Figure 5).
b-TrCP Binds to the Smad4 Phosphodegron
Smad4 is polyubiquitinated and degraded by b-TrCP (Wan et al.,
2004, 2005; Yang et al., 2006). We now show that the binding of
b-TrCP to Smad4 is not constitutive but finely regulated byGSK3
linker phosphorylations triggered by FGF and inhibited byWnt. In
Drosophila egg chambers, clonal analysis of slmbmutations (the
b-TrCP homolog) revealed high levels of Medea protein (the
Smad4 homolog), together with a high-BMP phenotype (Muzzo-
pappa and Wappner, 2005). The first two Smad4 GSK3 sitesChave been conserved in Drosophila, other insects, and even
planarians (data not shown), suggesting that linker phosphoryla-
tions represent an ancient mechanism that regulates Smad4 ac-
tivity during embryonic patterning.
The positive effect of threonine 277 phosphorylation on
Smad4 activity (Figure 6) and the presence of a transcriptional
activation domain in Smad4 suggest that coactivators might
bind to themonophosphorylated PxTP site to drive transcription.
A prime candidate is p300, which has been shown to bind to the
SAD domain of Smad4 (de Caestecker et al., 2000). Recently, it
has been found that the mediator of the Hippo pathway YAP
binds phosphorylated SP sites in the Smad1 sequence (Alarco´n
et al., 2009; Arago´n et al., 2011) through its WW domain. The
other mediator of the Hippo pathway, TAZ, has been shown to
bind active Smad2/3/4 complexes and to connect TGF-b
signaling to cell density (Varelas et al., 2008, 2010). It is therefore
tempting to speculate that TAZ or YAP may recognize the phos-
phorylated TP site in Smad4 acting as coactivators. Alternatively,
the Smad4 linker region might recruit other coactivators, de-
pending on cellular context. Future studies will be required to
identify Smad4 phospholinker-interacting proteins.
Signaling Insulation and Crosstalk
Wnt signaling depletes active GSK3 from the cytosol, potentially
affecting the phosphorylation of many proteins in addition to
b-catenin (Taelman et al., 2010; Vinyoles et al., 2014; Acebron
et al., 2014). This raises the general question of how signaling
pathways are normally insulated from, or integrated with, each
other. The regulation of Smad4 activity by Wnt, which is
observed only in the presence of MAPK activation (or by intro-
ducing a phospho-mimetic priming site) indicates that the choice
between insulation and crosstalk depends on priming kinases
regulated by growth factors.
In the Xenopus embryo, it has been determined that, shortly
after midblastula (stage 8.5), nuclear b-catenin, diphospho Erk,
and C-terminal phospho-Smad2 are found in dorsal-marginal
cells (Schohl and Fagotto, 2002). These protein distributions
result from a maternal Wnt signal, a marginal zone gradient of
FGF that starts on the dorsal side, and a Nodal/TGF-b gradient
emanating from the dorsal-vegetal pole (Figure 7K; De Robertis
and Kuroda, 2004). This may generate a perfect storm of growth
factor signals that converge on the Smad4 protein to generate
maximal transcriptional activation. In this view, the different ter-
ritories of the embryo would be shaped and defined by Wnt/
GSK3 and FGF/MAPK feeding on the Nodal/TGF-b morphogen
gradient. Other mechanisms including combinations of tran-
scription factors, such as Siamois/Twin and activated Smad2/
3/4 at the level of specific promoters, will be important as well
(Labbe´ et al., 2000; Reid et al., 2012).
Replacement of endogenous Smad4 with its GSK3 phos-
phorylation-resistant mutant in Xenopus embryos resulted in
the entire ectoderm becoming mesoderm. This suggests that
GSK3 inhibition of Smad4 plays an essential role in allowing
ectodermal differentiation in vivo and extends previous findings
in the field, indicating a key role for Smad4 in ectoderm specifi-
cation (Dupont et al., 2005, 2009). In addition, phosphorylation
of Smad4 by GSK3 serves to constrain the size of Spemann’s
organizer. The crosstalk between the Wnt and Nodal/TGF-bell Reports 9, 688–700, October 23, 2014 ª2014 The Authors 697
pathways at the level of Smad4 could help explain in part the
mysterious ‘‘competence modifier’’ effect observed in Xenopus,
in which xWnt8 mRNA does not induce mesoderm by itself, yet
greatly sensitizes the competence of ectoderm to respond to ac-
tivin/TGF-b (Sokol and Melton, 1992; Moon and Christian, 1992).
Smad4 Linker Phosphorylation and Tumor Suppression
In cancer, Smad4/DPC4 acts as a barrier for tumor progression
(Ding et al., 2011; Vogelstein et al., 2013). TGF-b signaling has
potent antiproliferative effects in epithelia through the activation
of cyclin-dependent kinase inhibitors such as p14Ink4b and
p21WAF1 (Hanahan and Weinberg, 2011). At early stages, many
tumors are driven by activation of the Ras/Erk and the Wnt
oncogenic pathways, which increase proliferation genes such
as cyclin D and c-Myc (Hanahan and Weinberg, 2011). In our
proposed mechanism, these mitogenic effects will be counter-
balanced by the increase in TGF-b/Smad4 antiproliferative activ-
ity mediated by MAPK and Wnt/GSK3 signaling. This barrier
effect of TGF-b is lost when the Smad4 tumor suppressor is
deleted or inhibited. The discovery that Smad4 activity is not
constitutive but instead regulated by growth factors helps under-
stand why its loss has such catastrophic consequences during
progression of pancreatic, colorectal, and prostate cancers.
Smad4 is frequently deleted in metastatic tumors, but intra-
genic point mutations are also found (Levy and Hill, 2006; Xu
and Attisano, 2000). Interestingly, several of these point muta-
tions increase Smad4 degradation by facilitating binding to
b-TrCP (Wan et al., 2005; Yang et al., 2006). Our finding that
b-TrCP binding to Smad4 is regulated by GSK3 phosphoryla-
tions suggests that pharmacological GSK3 inhibitors may stabi-
lize Smad4 and restore growth control in such tumors.
EXPERIMENTAL PROCEDURES
Mammalian Cell Culture
NIH 3T3, CAGA12-HaCaT, HEK293 (lacking T antigen, which respond very
well to TGF-b), L cells (ATCC no. CRL-2648), as well as L-Wnt3a cells (ATCC
no. CRL-2647) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (GIBCO) and cultured
at 37C in 5% CO2. MDA-MB-468 cells (which lack Smad4) were cultured in
DMEM:Ham’s-F12 (1:1 vol:vol). L cell control-conditioned medium and
Wnt3a-conditioned medium were prepared according to the ATCC protocol
(Willert et al., 2003), with the exception that 2%serumwas used.Wnt3a-condi-
tioned medium was further boosted by adding 200 ng/ml of recombinant mu-
rine Wnt3a protein (PeproTech). DNA constructs were transfected with BioT
(Bioland) 24 hr after plating cells. siRNAs were transfected with Lipofectamine
2000 using the reverse transfection protocol (Invitrogen) and analyzed after
48 hr. Cycloheximide (Sigma no. C-7698) was dissolved in ethanol and used
at a final concentration of 20 mg/ml (Taelman et al., 2010).
Antibodies
The following antibodies were used in this study: a-Smad4 monoclonal (Santa
Cruz Biotechnology B-8; 1:250), a-diphosphorylated ERK-1 and ERK-2 mono-
clonal (Sigma; 1:500), a-GAPDH (Cell Signaling Technology 14C10; 1:7,000),
a-Flag mouse (Sigma; 1:3,000), rabbit a-ubiquitin (Santa Cruz Biotechnology
FL-76; 1:200), a-hemagglutinin (HA) (Sigma; 1:3,000), rabbit a-b-TrCP
(Cell Signal D13F10; 1:800), and mouse a-Gal4DBD (Santa Cruz RK5C1;
1:200). Secondary antibodies used were IRDye 800CW Donkey anti-Rabbit
immunoglobulin G (IgG) (LI-COR Biosciences 926-32213; 1:5,000) and IRDye
680RD Donkey anti-Mouse IgG (LI-COR Biosciences 926-68072; 1:5,000).
For custom pSmad4GSK3 antibody, a synthetic peptide ([H]-CKK-Acp-
NSTTTWT(PO3)GSRT(PO3)APY-[NH2]) was used to immunize two rabbits698 Cell Reports 9, 688–700, October 23, 2014 ª2014 The Authors(Covance). The antiserum with the highest ELISA titer was positively affinity
purified and was used at a concentration of 1:5,000 for detection of endoge-
nous Smad4 phosphorylations and at 1:25,000 for overexpressed proteins.
Statistical Analyses
Results are given as the mean ± SEM. Statistical analyses were performed
with Excel (Microsoft), applying the two-tailed t test. Differences of means
were considered significant at a significance level of 0.05. The following sym-
bols are annotated: n.s., not significant (p > 0.05); *p% 0.05; **p% 0.01; ***p%
0.001.
Additional Methods
Detailed methods for cell culture, plasmid reagents, polyubiquitination assays,
western blotting, Phos-tag analyses, Xenopus embryo assays, quantitative
RT-PCR, Gal4DBD transcriptional assays, dissociation of Xenopus animal
cap cells, reporter gene assays, phosphatase treatment, and construction of
the new Smad4-Luc reporter gene are provided in Supplemental Experimental
Procedures.
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and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2014.09.020.
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